

2020/21 Month 10 Financial Performance

Author: Tarun Basra - Head of Financial Performance

Sponsor: Simon Lazarus - Chief Financial Officer

Paper H4

Purpose of Report:

| This paper is for: | Description | Select (X) |
|--------------------|--------------------------------------------------------------------------------------------------------------|------------|
| Decision | To formally receive a report and approve its recommendations OR a particular course of action | |
| Discussion | To discuss, in depth, a report noting its implications without formally approving a recommendation or action | X |
| Assurance | To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan | |
| Noting | For noting without the need for discussion | |

Previous Consideration:

| Meeting | Date | Please clarify the purpose of the paper to that meeting using the categories above |
|-------------------------------|----------|------------------------------------------------------------------------------------|
| CMG Board (specify which CMG) | | |
| FRB | | |
| FIC | 25.02.21 | Discussion |
| Trust Board | | |

Executive Summary

Context:

This paper updates the Trust Board on the financial performance of the Trust at Month 10 of 2020/21.

To support the Trust during COVID-19, NHSE&I are providing an upfront Top Up payment. This was estimated from the Trust's underlying financial position.

Questions:

1. What is the financial performance for the period ending 31st January 2021?

The actual position including Top Up funding is a £27.9m surplus, which is £9.1m favourable to forecast.

2. What are the main issues of note in the Month 7-10 financial performance?

The main issues are as follows:

- Lower pay expenditure than forecast of £3.7m, reflecting lower expenditure on winter (£0.4m), COVID-19 (£1m) and baseline costs (£2.2m)
- Lower non pay expenditure of £7.3m, reflecting lower expenditure on COVID-19 (£0.6m) and restoration and recovery (£0.4m) and baseline costs (£5.5m)
- Higher income of £1.3m, reflecting excluded drugs and devices
- Higher non-operating costs of £2.8m, reflecting amortisation due to the capitalisation of IT expenditure

3. What are the risks to financial performance in the remainder of the year?

- The scale and duration of the impact of COVID-19 on patient activity, income and expenditure is uncertain and will require ongoing refinement to forecasting of financial performance throughout the year aligned to restoration and recovery.

Input Sought:

The Trust Board is asked to:

- **Note** the Month 10 (2020/21) reported financial position

For Reference:

This report relates to the following UHL quality and supporting priorities:

1. Quality priorities

| | |
|------------------------------|----------------|
| Safe, surgery and procedures | Not applicable |
| Safely and timely discharge | Not applicable |
| Improved Cancer pathways | Not applicable |
| Streamlined emergency care | Not applicable |
| Better care pathways | Not applicable |
| Ward accreditation | Not applicable |

2. Supporting priorities

| | |
|---------------------------------------|----------------|
| People strategy implementation | Not applicable |
| Estate investment and reconfiguration | Not applicable |
| e-Hospital | Not applicable |
| More embedded research | Not applicable |
| Better corporate services | Not applicable |
| Quality strategy development | Not applicable |

3. Equality Impact Assessment and Patient and Public Involvement considerations

- What was the outcome of your Equality Impact Assessment (EIA)? **Not applicable**
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required. **None required**
- How did the outcome of the EIA influence your Patient and Public Involvement? **Not applicable**
- If an EIA was not carried out, what was the rationale for this decision? **Not applicable**

4. Risk and Assurance

Risk Reference:

| Does this paper reference a risk event? | Select (X) | Risk Description: |
|-------------------------------------------------------------------------------------------------|------------|---------------------------------------------|
| Strategic: Does this link to a <i>Principal Risk</i> on the BAF? | X | Principal Risk 4 – Financial Sustainability |
| Organisational: Does this link to an <i>Operational/Corporate Risk</i> on Datix Register | | |
| New Risk identified in paper: What <i>type</i> and <i>description</i> ? | | |
| None | | |

- 5. Scheduled date for the **next paper** on this topic: 1st April 2021
- 6. Executive Summaries should not exceed **5 sides** [My paper does/~~does not~~ comply]



Financial Performance Report

January 2021

One team shared values



Exec summary

Caring at its best

- The Trust has reported a YTD surplus of £27.9m. This is a £43.4m favourable variance to the planned deficit of £15.5m. The YTD month 10 position is £9.1m favourable to the forecast (Page 5 breaks this down by category of expenditure).
- After potential provisions of c£16m (including c£7m relating to 2019/20) which are being validated, the Trust is currently forecasting a £17.6m surplus at 31st March 2021. The Senior Finance Team are currently reviewing CMG and Directorate forecasts, and provisions to confirm the Trust's forecast outturn, which following Executive approval will be reported to the Trust Board on 4th March 2021. An update on this process will be provided at the Finance and Investment Committee on 25th February 2021.
- The driver for this improvement is lower recruitment levels than planned, reduced restoration and recovery activity, reduced winter fill due to staff shortages, increased income from Health Education England and significant underspends in non-pay as a result of reduced activity (Page 10 shows the detail by category).
- The Trust has reported a risk adjusted YTD CIP cash releasing position of £5.2m. The end of year forecast projection for non risk adjusted cash releasing CIP for months 7-12 is £9.1m (Page 12-13 details CIP delivery).

Key highlights (1/2)

Forecast


- The forecast reflects CMG and Directorate forecast outturns at month 10. The detail broken down by category is shown on page 10.
- CMGs have forecasted the ongoing impact of Covid-19 on restoration and recovery and elective activity, with an assumed increase in activity and expenditure in March.
- A £7m forecast provision has been included to reflect the risk of the 2019/20 accounts audit.
- A £1m forecast provision is included relating to Grant Thornton audit fees, KPMG and Deloitte fees, and the extension of Kingsgate.
- Additional provisions totalling £9.3m are included, which are subject to validation by the Senior Finance Team.
- The forecast assumes a risk of £3.8m of the loss of patient care income for the elective incentive scheme. This is still subject to national NHSEI guidance.
- It has been confirmed that national funding is to be provided for the increase in annual leave provision and the legal case relating to Flowers.
- The impact of the Covid-19 vaccination programme has been included into the forecast and that additional expenditure incurred will be fully funded.

Cash flow & Underlying Cash Position vs Operating Deficit


- The Trust cash position at the end of month 10 was £132.1m. After adjusting for payments received in advance the Trust underlying cash position is c£41.5m. The year end cash position is forecast to return to normalised levels (£16m), having now received confirmation that this current payment regime will end in March (i.e. no SLA income will be received in March). Capital payments will also accelerate in February and March inline with forecast, as well as settlement of the bi-annual PDC dividend charge.

Key highlights (2/2)


Pay Run Rate




Agency Run Rate



WLIs – Restoration and Recovery



WTE Run Rate as per CMGs



| | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 |
|----------------------------|--------|--------|--------|--------|--------|--------|
| — Covid-19 | 72.61 | 107.51 | 135.82 | 159.47 | 161.11 | 142.13 |
| — Restoration and recovery | 35.89 | 26.66 | 33.25 | 22.24 | 25.42 | 56.12 |
| — Winter | 6.61 | 48.58 | 77.58 | 82.19 | 141.67 | 141.67 |
| — CIP | -7.30 | -7.30 | -10.88 | -9.47 | -10.15 | -8.50 |

Summary financial position (M7-M12)

| | In month | | | YTD | | | FOT | | |
|------------------------------------------------|------------------|-----------------|---------------|------------------|------------------|---------------|------------------|-------------------------|---------------|
| | Forecast | Actual | Variance | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 |
| Patient care income | 76,508 | 80,022 | 3,514 | 315,863 | 319,376 | 3,514 | 477,290 | 477,068 | (222) |
| Other income | 28,341 | 26,119 | (2,222) | 105,858 | 103,636 | (2,222) | 154,486 | 159,812 | 5,326 |
| Total income | 104,849 | 106,141 | 1,292 | 421,720 | 423,013 | 1,292 | 631,776 | 636,880 | 5,104 |
| Pay costs | (63,949) | (60,218) | 3,731 | (246,325) | (242,594) | 3,731 | (375,171) | (366,079) | 9,091 |
| Non-pay costs | (36,178) | (28,903) | 7,274 | (138,623) | (131,349) | 7,274 | (231,287) | (221,228) | 10,058 |
| Total costs | (100,126) | (89,121) | 11,005 | (384,948) | (373,943) | 11,005 | (606,457) | (587,308) | 19,150 |
| EBITDA | 4,723 | 17,020 | 12,297 | 36,773 | 49,070 | 12,297 | 25,319 | 49,572 | 24,254 |
| Non-operating costs | (3,741) | (6,522) | (2,782) | (15,568) | (18,350) | (2,782) | (22,987) | (25,830) | (2,843) |
| Retained surplus / (deficit) | 982 | 10,497 | 9,515 | 21,205 | 30,720 | 9,515 | 2,332 | 23,743 | 21,411 |
| Donated assets | 77 | (308) | (385) | (2,400) | (2,785) | (385) | (2,246) | (6,120) | (3,874) |
| Net surplus / (deficit) | 1,059 | 10,189 | 9,130 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus/(deficit) against control total | 1,059 | 10,189 | 9,130 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |

Main areas of variance:

- **Patient Care Income (PCI):** Primarily relating to the Elective Incentive Scheme (EIS) and Excluded Drugs and Devices performance relating to specialised drugs
- **Total Pay Costs:** Reflecting lower recruitment levels than planned, reduced restoration and recovery activity and the reduced winter fill due to staff shortages
- **Non-Pay:** The favourable variance against plan is due to significant underspends as a result of reduced elective activity, lower than planned Covid-19 expenditure, and the impact of the capitalisation of the eQuip contract.
- **Non-operating costs:** The adverse variance reflects increased amortisation due to the capitalisation of the eQuip contract.

Appendix 1: total 2020/21 forecast (M7-M12)

| | Actual | Actual | Actual | Actual | Forecast | Forecast | Forecast | In month | | | YTD | | | FOT | | |
|------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|------------------|------------------|-----------------|---------------|------------------|------------------|---------------|------------------|-------------------------|---------------|
| | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Full year | Forecast | Actual | Variance | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 |
| Patient care income | 80,308 | 80,160 | 78,887 | 80,022 | 79,326 | 78,366 | 477,068 | 76,508 | 80,022 | 3,514 | 315,863 | 319,376 | 3,514 | 477,290 | 477,068 | (222) |
| Other income | 22,967 | 28,804 | 25,746 | 26,119 | 25,765 | 30,411 | 159,812 | 28,341 | 26,119 | (2,222) | 105,858 | 103,636 | (2,222) | 154,486 | 159,812 | 5,326 |
| Total income | 103,275 | 108,964 | 104,632 | 106,141 | 105,091 | 108,776 | 636,880 | 104,849 | 106,141 | 1,292 | 421,720 | 423,013 | 1,292 | 631,776 | 636,880 | 5,104 |
| Pay costs | (60,749) | (59,980) | (61,647) | (60,218) | (61,478) | (62,007) | (366,079) | (63,949) | (60,218) | 3,731 | (246,325) | (242,594) | 3,731 | (375,171) | (366,079) | 9,091 |
| Non-pay costs | (35,450) | (35,376) | (31,620) | (28,903) | (34,176) | (55,704) | (221,228) | (36,178) | (28,903) | 7,274 | (138,623) | (131,349) | 7,274 | (231,287) | (221,228) | 10,058 |
| Total costs | (96,199) | (95,356) | (93,267) | (89,121) | (95,654) | (117,711) | (587,308) | (100,126) | (89,121) | 11,005 | (384,948) | (373,943) | 11,005 | (606,457) | (587,308) | 19,150 |
| EBITDA | 7,076 | 13,608 | 11,366 | 17,020 | 9,437 | (8,934) | 49,572 | 4,723 | 17,020 | 12,297 | 36,773 | 49,070 | 12,297 | 25,319 | 49,572 | 24,254 |
| Non-operating costs | (4,740) | (3,629) | (3,458) | (6,522) | (3,740) | (3,741) | (25,830) | (3,741) | (6,522) | (2,782) | (15,568) | (18,350) | (2,782) | (22,987) | (25,830) | (2,843) |
| Retained surplus / (deficit) | 2,336 | 9,979 | 7,907 | 10,497 | 5,697 | (12,675) | 23,743 | 982 | 10,497 | 9,515 | 21,205 | 30,720 | 9,515 | 2,332 | 23,743 | 21,411 |
| Donated assets | 66 | (2,593) | 50 | (308) | 77 | (3,412) | (6,120) | 77 | (308) | (385) | (2,400) | (2,785) | (385) | (2,246) | (6,120) | (3,874) |
| Net surplus / (deficit) | 2,402 | 7,386 | 7,958 | 10,189 | 5,774 | (16,087) | 17,623 | 1,059 | 10,189 | 9,130 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus/(deficit) against control total | 2,402 | 7,386 | 7,958 | 10,189 | 5,774 | (16,087) | 17,623 | 1,059 | 10,189 | 9,130 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |

Appendix 2: break down of total forecast (1/3)

| | In month | | | YTD | | | FOT | | |
|--------------------------------------------------|-----------------|-----------------|--------------|------------------|------------------|--------------|------------------|-------------------------|---------------|
| | Forecast | Actual | Variance | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 |
| Baseline forecast | | | | | | | | | |
| Patient care income | 76,508 | 80,022 | 3,514 | 315,863 | 319,376 | 3,514 | 477,290 | 477,068 | (222) |
| Other income | 24,113 | 22,228 | (1,885) | 89,176 | 87,291 | (1,885) | 128,865 | 134,250 | 5,385 |
| Total income | 100,622 | 102,250 | 1,629 | 405,039 | 406,668 | 1,629 | 606,154 | 611,318 | 5,164 |
| Pay costs | (61,654) | (59,445) | 2,209 | (242,540) | (240,331) | 2,209 | (365,555) | (361,799) | 3,756 |
| Non pay costs | (34,807) | (29,264) | 5,543 | (135,034) | (129,492) | 5,542 | (224,851) | (215,484) | 9,367 |
| Total costs | (96,461) | (88,710) | 7,751 | (377,575) | (369,823) | 7,751 | (590,406) | (577,283) | 13,123 |
| EBITDA | 4,161 | 13,541 | 9,380 | 27,464 | 36,844 | 9,380 | 15,748 | 34,035 | 18,287 |
| Non-operating costs | (3,741) | (6,522) | (2,782) | (15,568) | (18,350) | (2,782) | (22,987) | (25,830) | (2,843) |
| Retained surplus / (deficit) | 420 | 7,018 | 6,598 | 11,896 | 18,494 | 6,598 | (7,239) | 8,205 | 15,444 |
| Donated assets | 77 | (308) | (385) | (2,400) | (2,785) | (385) | (2,246) | (6,120) | (3,874) |
| Net deficit | 497 | 6,711 | 6,213 | 9,496 | 15,710 | 6,213 | (9,484) | 2,086 | 11,570 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | 497 | 6,711 | 6,213 | 9,496 | 15,710 | 6,213 | (9,484) | 2,086 | 11,570 |
| COVID | | | | | | | | | |
| Patient care income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income | 4,149 | 3,764 | (385) | 16,216 | 15,831 | (385) | 24,937 | 24,913 | (24) |
| Total income | 4,149 | 3,764 | (385) | 16,216 | 15,831 | (385) | 24,937 | 24,913 | (24) |
| Pay costs | (1,877) | (922) | 955 | (3,216) | (2,261) | 955 | (6,710) | (4,302) | 2,408 |
| Non pay costs | (1,007) | (396) | 611 | (2,915) | (2,304) | 611 | (5,049) | (6,424) | (1,375) |
| Total costs | (2,884) | (1,319) | 1,565 | (6,131) | (4,565) | 1,565 | (11,759) | (10,726) | 1,033 |
| EBITDA | 1,265 | 2,446 | 1,180 | 10,085 | 11,266 | 1,180 | 13,178 | 14,187 | 1,009 |
| Non-operating costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained surplus / (deficit) | 1,265 | 2,446 | 1,180 | 10,085 | 11,266 | 1,180 | 13,178 | 14,187 | 1,009 |
| Donated assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net deficit | 1,265 | 2,446 | 1,180 | 10,085 | 11,266 | 1,180 | 13,178 | 14,187 | 1,009 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | 1,265 | 2,446 | 1,180 | 10,085 | 11,266 | 1,180 | 13,178 | 14,187 | 1,009 |

Appendix 2: break down of total forecast (2/3)

| | In month | | | YTD | | | FOT | | |
|--------------------------------------------------|--------------|--------------|------------|----------------|----------------|------------|----------------|-------------------------|--------------|
| | Forecast | Actual | Variance | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 |
| Restoration and recovery | | | | | | | | | |
| Patient care income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pay costs | (251) | (143) | 108 | (1,350) | (1,242) | 108 | (2,986) | (1,753) | 1,233 |
| Non pay costs | (724) | (349) | 374 | (2,167) | (1,792) | 374 | (3,862) | (2,833) | 1,029 |
| Total costs | (974) | (492) | 482 | (3,517) | (3,034) | 482 | (6,848) | (4,586) | 2,262 |
| EBITDA | (974) | (492) | 482 | (3,517) | (3,034) | 482 | (6,848) | (4,586) | 2,262 |
| Non-operating costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained surplus / (deficit) | (974) | (492) | 482 | (3,517) | (3,034) | 482 | (6,848) | (4,586) | 2,262 |
| Donated assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net deficit | (974) | (492) | 482 | (3,517) | (3,034) | 482 | (6,848) | (4,586) | 2,262 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | (974) | (492) | 482 | (3,517) | (3,034) | 482 | (6,848) | (4,586) | 2,262 |
| Winter pressures | | | | | | | | | |
| Patient care income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pay costs | (722) | (335) | 387 | (1,283) | (896) | 387 | (3,010) | (1,701) | 1,309 |
| Non pay costs | (114) | (82) | 32 | (320) | (288) | 32 | (372) | (372) | 0 |
| Total costs | (836) | (417) | 419 | (1,603) | (1,184) | 419 | (3,382) | (2,073) | 1,309 |
| EBITDA | (836) | (417) | 419 | (1,603) | (1,184) | 419 | (3,382) | (2,073) | 1,309 |
| Non-operating costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained surplus / (deficit) | (836) | (417) | 419 | (1,603) | (1,184) | 419 | (3,382) | (2,073) | 1,309 |
| Donated assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net deficit | (836) | (417) | 419 | (1,603) | (1,184) | 419 | (3,382) | (2,073) | 1,309 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | (836) | (417) | 419 | (1,603) | (1,184) | 419 | (3,382) | (2,073) | 1,309 |

Appendix 2: break down of total forecast (3/3)

| | In month | | | YTD | | | FOT | | |
|--------------------------------------------------|------------------|-----------------|---------------|------------------|------------------|---------------|------------------|-------------------------|---------------|
| | Forecast | Actual | Variance | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 | £000 |
| CIP savings | | | | | | | | | |
| Patient care income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income | 78 | 127 | 48 | 466 | 514 | 48 | 684 | 649 | (35) |
| Total income | 78 | 127 | 48 | 466 | 514 | 48 | 684 | 649 | (35) |
| Pay costs | 555 | 627 | 72 | 2,065 | 2,136 | 72 | 3,090 | 3,475 | 385 |
| Non pay costs | 474 | 1,188 | 715 | 1,813 | 2,528 | 715 | 2,848 | 3,885 | 1,037 |
| Total costs | 1,029 | 1,816 | 787 | 3,877 | 4,664 | 787 | 5,938 | 7,360 | 1,422 |
| EBITDA | 1,107 | 1,942 | 835 | 4,343 | 5,178 | 835 | 6,622 | 8,009 | 1,387 |
| Non-operating costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained surplus / (deficit) | 1,107 | 1,942 | 835 | 4,343 | 5,178 | 835 | 6,622 | 8,009 | 1,387 |
| Donated assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net deficit | 1,107 | 1,942 | 835 | 4,343 | 5,178 | 835 | 6,622 | 8,009 | 1,387 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | 1,107 | 1,942 | 835 | 4,343 | 5,178 | 835 | 6,622 | 8,009 | 1,387 |
| Total forecast | | | | | | | | | |
| Patient Care Income | 76,508 | 80,022 | 3,514 | 315,863 | 319,376 | 3,514 | 477,290 | 477,068 | (222) |
| Other Income | 28,341 | 26,119 | (2,222) | 105,858 | 103,636 | (2,222) | 154,486 | 159,812 | 5,326 |
| Total Income | 104,849 | 106,141 | 1,292 | 421,720 | 423,013 | 1,292 | 631,776 | 636,880 | 5,104 |
| Pay costs | (63,949) | (60,218) | 3,731 | (246,325) | (242,594) | 3,731 | (375,171) | (366,079) | 9,091 |
| Non pay costs | (36,178) | (28,903) | 7,274 | (138,623) | (131,349) | 7,274 | (231,287) | (221,228) | 10,058 |
| Total costs | (100,126) | (89,121) | 11,005 | (384,948) | (373,943) | 11,005 | (606,457) | (587,308) | 19,150 |
| EBITDA | 4,723 | 17,020 | 12,297 | 36,773 | 49,070 | 12,297 | 25,319 | 49,572 | 24,254 |
| Non-operating costs | (3,185) | (5,895) | (2,710) | (15,568) | (18,350) | (2,782) | (22,987) | (25,830) | (2,843) |
| Retained surplus / (deficit) | 2,847 | 12,730 | 9,883 | 21,205 | 30,720 | 9,515 | 2,332 | 23,743 | 21,411 |
| Donated assets | 77 | (308) | (385) | (2,400) | (2,785) | (385) | (2,246) | (6,120) | (3,874) |
| Net deficit | 1,895 | 10,606 | 8,711 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |
| Provider sustainability fund | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surplus / (deficit) against control total | 1,059 | 10,189 | 9,130 | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |

Appendix 3 – forecast outturn analysis

| | | M7-M12 Forecast @ M9 £'000 | | | | | | | M7-12 Actuals/FOT @ M10 £'000 | | | | | | | M7-M12 - Actuals/FOT Variance @ M10 £'000 | | | | | | |
|------------------------------|-----------------------------------|----------------------------|----------------|----------------|--------------|----------------|------------------|------------------|-------------------------------|----------------|----------------|--------------|--------------|------------------|------------------|-------------------------------------------|--------------|--------------|--------------|---------------|---------------|---------------|
| | | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP Rec | CIP Non Rec | Baseline | Total |
| I&E | NHS Patient Income | 0 | 0 | 0 | 0 | 0 | 477,290 | 477,290 | 0 | 0 | 0 | 0 | 0 | 477,068 | 477,068 | 0 | 0 | 0 | 0 | 0 | (222) | (222) |
| | Other Operating Income | 24,937 | 0 | 0 | 249 | 435 | 128,865 | 154,486 | 24,913 | 0 | 0 | 228 | 421 | 134,250 | 159,812 | (24) | 0 | 0 | (21) | (14) | 5,385 | 5,326 |
| | Total Income | 24,937 | 0 | 0 | 249 | 435 | 606,154 | 631,776 | 24,913 | 0 | 0 | 228 | 421 | 611,318 | 636,880 | (24) | 0 | 0 | (21) | (14) | 5,164 | 5,104 |
| | Non Agency Pay | (5,549) | (2,668) | (1,735) | 942 | 1,606 | (355,495) | (362,899) | (3,218) | (1,460) | (1,052) | 897 | 2,177 | (351,935) | (354,592) | 2,331 | 1,208 | 683 | (45) | 571 | 3,560 | 8,307 |
| | Agency Pay | (1,160) | (317) | (1,275) | 503 | 38 | (10,061) | (12,272) | (1,083) | (293) | (648) | 363 | 38 | (9,864) | (11,487) | 77 | 25 | 627 | (140) | 0 | 196 | 785 |
| | Non-pay | (5,049) | (3,862) | (372) | 2,196 | 652 | (224,851) | (231,287) | (6,424) | (2,833) | (372) | 2,428 | 1,457 | (215,484) | (221,228) | (1,375) | 1,029 | 0 | 232 | 805 | 9,367 | 10,058 |
| | Total Operating Costs | (11,759) | (6,848) | (3,382) | 3,642 | 2,296 | (590,406) | (606,457) | (10,726) | (4,586) | (2,073) | 3,689 | 3,672 | (577,283) | (587,308) | 1,033 | 2,262 | 1,309 | 47 | 1,376 | 13,123 | 19,150 |
| | EBITDA | 13,178 | (6,848) | (3,382) | 3,891 | 2,731 | 15,748 | 25,319 | 14,187 | (4,586) | (2,073) | 3,916 | 4,093 | 34,035 | 49,572 | 1,009 | 2,262 | 1,309 | 25 | 1,362 | 18,287 | 24,254 |
| | Non Operating Costs | 0 | 0 | 0 | 0 | 0 | (22,987) | (22,987) | 0 | 0 | 0 | 0 | 0 | (25,830) | (25,830) | 0 | 0 | 0 | 0 | 0 | (2,843) | (2,843) |
| | Retained Surplus/(Deficit) | 13,178 | (6,848) | (3,382) | 3,891 | 2,731 | (7,239) | 2,332 | 14,187 | (4,586) | (2,073) | 3,916 | 4,093 | 8,205 | 23,743 | 1,009 | 2,262 | 1,309 | 25 | 1,362 | 15,444 | 21,411 |
| Donated Assets | 0 | 0 | 0 | 0 | 0 | (2,246) | (2,246) | 0 | 0 | 0 | 0 | 0 | (6,120) | (6,120) | 0 | 0 | 0 | 0 | 0 | (3,874) | (3,874) | |
| Net Surplus/(Deficit) | 13,178 | (6,848) | (3,382) | 3,891 | 2,731 | (9,484) | 86 | 14,187 | (4,586) | (2,073) | 3,916 | 4,093 | 2,086 | 17,623 | 1,009 | 2,262 | 1,309 | 25 | 1,362 | 11,570 | 17,537 | |

| | | M10 YTD Forecast @ M9 £'000 | | | | | | | YTD Actuals/FOT @ M10 £'000 | | | | | | | YTD - Actuals/FOT @ M10 Variance £'000 | | | | | | |
|------------------------------|-----------------------------------|-----------------------------|----------------|----------------|--------------|--------------|------------------|------------------|-----------------------------|----------------|----------------|--------------|---------------|------------------|------------------|----------------------------------------|------------|-------------|-------------|--------------|--------------|---------------|
| | | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP Rec | CIP Non Rec | Baseline | Total |
| I&E | NHS Patient Income | 0 | 0 | 0 | 0 | 0 | 315,863 | 315,863 | 0 | 0 | 0 | 0 | 0 | 319,376 | 319,376 | 0 | 0 | 0 | 0 | 0 | 3,514 | 3,514 |
| | Other Operating Income | 16,216 | 0 | 0 | 209 | 257 | 89,176 | 105,858 | 15,831 | 0 | 0 | 187 | 327 | 87,291 | 103,636 | (385) | 0 | 0 | (21) | 70 | (1,885) | (2,222) |
| | Total Income | 16,216 | 0 | 0 | 209 | 257 | 405,039 | 421,720 | 15,831 | 0 | 0 | 187 | 327 | 406,668 | 423,013 | (385) | 0 | 0 | (21) | 70 | 1,629 | 1,292 |
| | Non Agency Pay | (2,558) | (1,179) | (760) | 647 | 1,073 | (235,954) | (238,729) | (1,675) | (1,070) | (598) | 605 | 1,308 | (233,934) | (235,365) | 883 | 109 | 162 | (43) | 235 | 2,019 | 3,365 |
| | Agency Pay | (658) | (171) | (524) | 306 | 38 | (6,587) | (7,595) | (586) | (172) | (298) | 186 | 38 | (6,397) | (7,229) | 72 | (1) | 226 | (120) | 0 | 190 | 366 |
| | Non-pay | (2,915) | (2,167) | (320) | 1,386 | 426 | (135,034) | (138,623) | (2,304) | (1,792) | (288) | 1,544 | 984 | (129,492) | (131,349) | 611 | 374 | 32 | 157 | 557 | 5,542 | 7,274 |
| | Total Operating Costs | (6,131) | (3,517) | (1,603) | 2,340 | 1,537 | (377,575) | (384,948) | (4,565) | (3,034) | (1,184) | 2,335 | 2,329 | (369,823) | (373,943) | 1,565 | 482 | 419 | (5) | 792 | 7,751 | 11,005 |
| | EBITDA | 10,085 | (3,517) | (1,603) | 2,549 | 1,795 | 27,464 | 36,773 | 11,266 | (3,034) | (1,184) | 2,522 | 2,656 | 36,844 | 49,070 | 1,180 | 482 | 419 | (27) | 862 | 9,380 | 12,297 |
| | Non Operating Costs | 0 | 0 | 0 | 0 | 0 | (15,568) | (15,568) | 0 | 0 | 0 | 0 | 0 | (18,350) | (18,350) | 0 | 0 | 0 | 0 | 0 | (2,782) | (2,782) |
| | Retained Surplus/(Deficit) | 10,085 | (3,517) | (1,603) | 2,549 | 1,795 | 11,896 | 21,205 | 11,266 | (3,034) | (1,184) | 2,522 | 2,656 | 18,494 | 30,720 | 1,180 | 482 | 419 | (27) | 862 | 6,598 | 9,515 |
| Donated Assets | 0 | 0 | 0 | 0 | 0 | (2,400) | (2,400) | 0 | 0 | 0 | 0 | 0 | (2,785) | (2,785) | 0 | 0 | 0 | 0 | 0 | (385) | (385) | |
| Net Surplus/(Deficit) | 10,085 | (3,517) | (1,603) | 2,549 | 1,795 | 9,496 | 18,805 | 11,266 | (3,034) | (1,184) | 2,522 | 2,656 | 15,710 | 27,935 | 1,180 | 482 | 419 | (27) | 862 | 6,213 | 9,130 | |

| | | M10 Forecast @ M9 £'000 | | | | | | | M10 Actuals £'000 | | | | | | | M10 FOT Variance £'000 | | | | | | |
|------------------------------|-----------------------------------|-------------------------|--------------|--------------|------------|-------------|-----------------|------------------|-------------------|--------------|--------------|--------------|--------------|-----------------|-----------------|------------------------|------------|-------------|-------------|--------------|--------------|---------------|
| | | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP | CIP Non Rec | Baseline | Total | Covid | R&R | Winter | CIP Rec | CIP Non Rec | Baseline | Total |
| I&E | NHS Patient Income | 0 | 0 | 0 | 0 | 0 | 76,508 | 76,508 | 0 | 0 | 0 | 0 | 0 | 80,022 | 80,022 | 0 | 0 | 0 | 0 | 0 | 3,514 | 3,514 |
| | Other Operating Income | 4,149 | 0 | 0 | 20 | 58 | 24,113 | 28,341 | 3,764 | 0 | 0 | (1) | 128 | 22,228 | 26,119 | (385) | 0 | 0 | (21) | 70 | (1,885) | (2,222) |
| | Total Income | 4,149 | 0 | 0 | 20 | 58 | 100,622 | 104,849 | 3,764 | 0 | 0 | (1) | 128 | 102,250 | 106,141 | (385) | 0 | 0 | (21) | 70 | 1,629 | 1,292 |
| | Non Agency Pay | (1,626) | (189) | (398) | 146 | 314 | (59,984) | (61,737) | (743) | (79) | (236) | 103 | 548 | (57,965) | (58,372) | 883 | 109 | 162 | (43) | 235 | 2,019 | 3,365 |
| | Agency Pay | (251) | (62) | (325) | 96 | 0 | (1,670) | (2,212) | (179) | (63) | (99) | (24) | 0 | (1,480) | (1,846) | 72 | (1) | 226 | (120) | 0 | 190 | 366 |
| | Non-pay | (1,007) | (724) | (114) | 407 | 66 | (34,807) | (36,178) | (396) | (349) | (82) | 565 | 623 | (29,264) | (28,903) | 611 | 374 | 32 | 157 | 557 | 5,543 | 7,274 |
| | Total Operating Costs | (2,884) | (974) | (836) | 649 | 380 | (96,461) | (100,126) | (1,319) | (492) | (417) | 644 | 1,172 | (88,710) | (89,121) | 1,565 | 482 | 419 | (5) | 792 | 7,751 | 11,005 |
| | EBITDA | 1,265 | (974) | (836) | 669 | 438 | 4,161 | 4,723 | 2,446 | (492) | (417) | 643 | 1,300 | 13,541 | 17,020 | 1,180 | 482 | 419 | (27) | 862 | 9,380 | 12,297 |
| | Non Operating Costs | 0 | 0 | 0 | 0 | 0 | (3,741) | (3,741) | 0 | 0 | 0 | 0 | 0 | (6,522) | (6,522) | 0 | 0 | 0 | 0 | 0 | (2,782) | (2,782) |
| | Retained Surplus/(Deficit) | 1,265 | (974) | (836) | 669 | 438 | 420 | 982 | 2,446 | (492) | (417) | 643 | 1,300 | 7,018 | 10,497 | 1,180 | 482 | 419 | (27) | 862 | 6,598 | 9,515 |
| Donated Assets | 0 | 0 | 0 | 0 | 0 | 77 | 77 | 0 | 0 | 0 | 0 | 0 | (308) | (308) | 0 | 0 | 0 | 0 | 0 | (385) | (385) | |
| Net Surplus/(Deficit) | 1,265 | (974) | (836) | 669 | 438 | 497 | 1,059 | 2,446 | (492) | (417) | 643 | 1,300 | 6,711 | 10,189 | 1,180 | 482 | 419 | (27) | 862 | 6,213 | 9,130 | |

Appendix 4: WTE, pay and WLI breakdown

| | Actual | Actual | Actual | Actual | Actual | Actual | Actual | Actual | Actual | Actual | Forecast | Forecast | In month | | |
|---------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|-------------|
| | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Forecast M10 | Actual M10 | Variance |
| Baseline forecast | | | | | | | | | | | | | | | |
| Substantive | 13907 | 13937 | 13863 | 13848 | 13887 | 13829 | 13811 | 13793 | 13828 | 13812 | 13865 | 13879 | 13933 | 13812 | -120 |
| Bank | 570 | 509 | 522 | 640 | 722 | 717 | 755 | 656 | 608 | 588 | 563 | 608 | 662 | 588 | -74 |
| Agency | 225 | 232 | 298 | 144 | 309 | 307 | 312 | 329 | 303 | 340 | 342 | 342 | 343 | 340 | -3 |
| Sub-total | 14701 | 14678 | 14683 | 14631 | 14918 | 14853 | 14877 | 14778 | 14739 | 14740 | 14770 | 14830 | 14938 | 14740 | -197 |
| COVID | | | | | | | | | | | | | | | |
| Substantive | 0 | 0 | 28 | 41 | 10 | 6 | 12 | 9 | 8 | 8 | 9 | 9 | 9 | 8 | 0 |
| Bank | 97 | 94 | 64 | 47 | 35 | 19 | 31 | 59 | 65 | 99 | 87 | 70 | 76 | 99 | 23 |
| Agency | 17 | 13 | 23 | 24 | 10 | 22 | 30 | 40 | 63 | 52 | 66 | 64 | 68 | 52 | -16 |
| Sub-total | 113 | 107 | 116 | 112 | 55 | 47 | 73 | 108 | 136 | 159 | 161 | 142 | 153 | 159 | 7 |
| Restoration and recovery | | | | | | | | | | | | | | | |
| Substantive | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 18 | 18 | 10 | 12 | 29 | 18 | 10 | -8 |
| Bank | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 7 | 12 | 1 | 2 | 13 | 9 | 1 | -8 |
| Agency | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 11 | 11 | 14 | 5 | 11 | 6 |
| Sub-total | 0 | 0 | 0 | 0 | 0 | 0 | 36 | 27 | 33 | 22 | 25 | 56 | 32 | 22 | -10 |
| Winter pressures | | | | | | | | | | | | | | | |
| Substantive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 17 | 21 | 18 | 18 | 16 | 21 | 5 |
| Bank | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 23 | 41 | 44 | 80 | 80 | 82 | 44 | -39 |
| Agency | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 10 | 19 | 17 | 43 | 43 | 53 | 17 | -36 |
| Sub-total | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 49 | 78 | 82 | 142 | 142 | 152 | 82 | -70 |
| CIP savings | | | | | | | | | | | | | | | |
| Substantive | 0 | 0 | 0 | 0 | 0 | 0 | -7 | -7 | -11 | -9 | -10 | -8 | -9 | -9 | 0 |
| Bank | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Agency | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sub-total | 0 | 0 | 0 | 0 | 0 | 0 | -7 | -7 | -11 | -9 | -10 | -8 | -9 | -9 | 0 |
| Total forecast | | | | | | | | | | | | | | | |
| Substantive | 13907 | 13937 | 13892 | 13889 | 13896 | 13835 | 13836 | 13827 | 13861 | 13843 | 13894 | 13927 | 13966 | 13843 | -123 |
| Bank | 666 | 603 | 586 | 687 | 758 | 736 | 802 | 745 | 726 | 732 | 732 | 770 | 830 | 732 | -98 |
| Agency | 241 | 245 | 321 | 167 | 319 | 329 | 347 | 382 | 388 | 420 | 462 | 464 | 469 | 420 | -49 |
| Total | 14815 | 14784 | 14799 | 14743 | 14973 | 14901 | 14985 | 14954 | 14975 | 14995 | 15088 | 15161 | 15265 | 14995 | -270 |

Appendix 5: update on CIP (M7-M12) (1/2)

| Planned | 20/21 Months 7-12 £'000 | | | | | | |
|--------------------------------------------|-------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Oct | Nov | Dec | Jan | Feb | Mar | Total |
| Cash releasing saving - Oct 20 to Mar 21 | 1,082 | 1,029 | 1,045 | 1,509 | 1,257 | 2,078 | 8,000 |
| Non Cash Releasing / Clinical Productivity | 24 | 19 | 14 | 19 | 19 | 19 | 115 |
| Total All | 1,106 | 1,048 | 1,059 | 1,528 | 1,276 | 2,097 | 8,115 |

| Actual / Forecast | 20/21 Months 7-12 £'000 | | | | | | |
|--------------------------------------------|-------------------------|--------------|--------------|--------------|--------------|--------------|---------------|
| | Oct | Nov | Dec | Jan | Feb | Mar | Total |
| Cash releasing saving - Oct 20 to Mar 21 | 685 | 1,333 | 1,217 | 1,942 | 1,620 | 2,304 | 9,102 |
| Non Cash Releasing / Clinical Productivity | 363 | 282 | 290 | 290 | 182 | 182 | 1,589 |
| Total All | 1,049 | 1,616 | 1,507 | 2,232 | 1,802 | 2,486 | 10,692 |


| Actual / Forecast (Risk Adjusted) | 20/21 Months 7-12 £'000 | | | | | | |
|--------------------------------------------|-------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Oct | Nov | Dec | Jan | Feb | Mar | Total |
| Cash releasing saving - Oct 20 to Mar 21 | 685 | 1,333 | 1,217 | 1,942 | 1,359 | 1,472 | 8,009 |
| Non Cash Releasing / Clinical Productivity | 363 | 282 | 290 | 290 | 178 | 178 | 1,581 |
| Total All | 1,049 | 1,616 | 1,507 | 2,232 | 1,537 | 1,649 | 9,590 |

The risk adjusted schemes figures are valued in the above table at 100% (Green), 25% (Amber) and 0% (Red)


| Variance to Plan (Risk Adjusted) | 20/21 Months 7-12 £'000 | | | | | | |
|--------------------------------------------|-------------------------|------------|------------|------------|------------|--------------|--------------|
| | Oct | Nov | Dec | Jan | Feb | Mar | Total |
| Cash releasing saving - Oct 20 to Mar 21 | (397) | 304 | 172 | 433 | 103 | (606) | 9 |
| Non Cash Releasing / Clinical Productivity | 339 | 264 | 276 | 271 | 158 | 158 | 1,466 |
| Total All | (57) | 568 | 448 | 704 | 261 | (448) | 1,475 |

Appendix 5: update on CIP (2/2)


Cumulative Actual / Forecast Outturn by Type £'000 - Oct 20 to Mar 21 Cash Releasing Schemes Only




Cumulative Actual / Forecast Outturn by CMG £'000 - Oct 20 to Mar 21 Cash Releasing Schemes Only




Plan and Actual / Forecast by Enabling Workstream Oct 20 to Mar 21 £'000 - All Schemes



Forecast CIP Delivery by Planning Risk - Oct 20 to Mar 21 All Schemes £'000



Forecast CIP Delivery by Delivery Risk - Oct 20 to Mar 21 All Schemes £'000



Appendix 6: activity and SLA income

| Point of delivery | FY19/20 YTD (M7-12) | | Activity YTD (M7-12) | | | Income YTD £000 (M7-12) | | | Income forecast £000 (M7-12) | | |
|----------------------------------------|---------------------|----------------|----------------------|------------------|------------------|-------------------------|----------------|--------------|------------------------------|-------------------|--------------|
| | Activity | Income £000 | Plan | Actual | Variance | Plan | Actual | Variance | Previous Month Forecast | Potential outturn | Variance |
| Emergency department | 87,508 | 13,676 | 80,943 | 61,583 | (19,360) | 13,480 | 10,193 | (3,287) | 17,646 | 16,681 | (964) |
| Day cases | 36,413 | 20,965 | 28,996 | 27,159 | (1,837) | 17,846 | 14,948 | (2,898) | 22,303 | 21,343 | (961) |
| Elective | 6,464 | 26,657 | 5,213 | 4,351 | (862) | 22,858 | 17,424 | (5,433) | 27,763 | 25,355 | (2,408) |
| Non elective | 41,663 | 91,351 | 39,306 | 35,058 | (4,248) | 91,104 | 78,926 | (12,178) | 126,043 | 119,958 | (6,085) |
| Outpatient – first | 89,429 | 17,145 | 80,913 | 64,416 | (16,497) | 15,807 | 10,648 | (5,158) | 18,145 | 16,785 | (1,361) |
| Outpatient – follow up | 213,135 | 18,122 | 192,032 | 191,377 | (655) | 17,648 | 12,414 | (5,235) | 21,137 | 19,728 | (1,409) |
| Outpatient procedures | 54,496 | 7,729 | 42,060 | 36,034 | (6,026) | 6,533 | 5,689 | (844) | 8,328 | 8,076 | (253) |
| Critical care services | 20,923 | 21,095 | 18,660 | 16,889 | (1,771) | 19,209 | 16,835 | (2,374) | 24,617 | 25,482 | 865 |
| Renal dialysis and transplant | 65,343 | 10,734 | 64,695 | 64,610 | (85) | 10,461 | 10,146 | (315) | 15,351 | 15,125 | (226) |
| Other central SLA income | 2,809,392 | 50,081 | 2,743,981 | 2,608,779 | (135,202) | 65,722 | 102,191 | 36,469 | 135,017 | 148,297 | 13,280 |
| Excluded devices & Medicines | 12,724 | 34,948 | - | 9,846 | 9,846 | 32,348 | 39,962 | 7,614 | 60,939 | 60,239 | (701) |
| Total SLA income (before fines) | 3,437,491 | 312,502 | 3,296,798 | 3,120,102 | (176,697) | 313,015 | 319,376 | 6,361 | 477,290 | 477,068 | (222) |
| Fines and penalties | - | (286) | - | - | - | - | - | - | - | - | - |
| Total SLA income (after fines) | 3,437,491 | 312,216 | 3,296,798 | 3,120,102 | (176,697) | 313,015 | 319,376 | 6,361 | 477,290 | 477,068 | (222) |

As a result of the interim financial arrangements in place during COVID, all NHS providers are paid a block payment from commissioners at values set nationally by NHSE/I. The Trust has aligned its patient care income plan with these block payments, although there are still some variances to the plan which are due to variable elements within the block contract and patient care income which is not included within the block amount.

Although income is blocked, the Trust continues to report significant reductions in activity due to COVID.

Elective services are continuing to see the impact of Covid-19, with Non-Elective Inpatients and Critical Care services being impacted to a lesser degree. Renal Dialysis and Transplant is the only service with activity in line with last year's performance.

Appendix 7: financial performance by CMG and directorate (1/2)

| | Trust overall | | | | | |
|------------------------------|------------------|------------------|---------------|--------------------|-------------------------|---------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 421,720 | 423,013 | 1,292 | 631,776 | 636,880 | 5,104 |
| Total Pay | (246,325) | (242,594) | 3,731 | (375,171) | (366,079) | 9,091 |
| Non Pay | (138,623) | (131,349) | 7,274 | (231,287) | (221,228) | 10,058 |
| Total Expenditure | (384,948) | (373,943) | 11,005 | (606,457) | (587,308) | 19,150 |
| EBITDA | 36,773 | 49,070 | 12,297 | 25,319 | 49,572 | 24,254 |
| Non Operating Costs | (15,568) | (18,350) | (2,782) | (22,987) | (25,830) | (2,843) |
| Donated Assets | (2,400) | (2,785) | (385) | (2,246) | (6,120) | (3,874) |
| Net Surplus/(Deficit) | 18,805 | 27,935 | 9,130 | 86 | 17,623 | 17,537 |

| | CHUGGS | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 65,743 | 65,504 | (240) | 98,522 | 98,334 | (188) |
| Total Pay | (22,235) | (21,959) | 276 | (33,712) | (33,107) | 605 |
| Non Pay | (25,520) | (25,081) | 439 | (38,962) | (37,915) | 1,047 |
| Total Expenditure | (47,755) | (47,041) | 714 | (72,674) | (71,022) | 1,652 |
| EBITDA | 17,988 | 18,463 | 475 | 25,848 | 27,312 | 1,464 |

| | CSI | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 21,982 | 21,702 | (280) | 33,815 | 34,137 | 322 |
| Total Pay | (33,445) | (33,435) | 10 | (50,678) | (50,992) | (314) |
| Non Pay | (5,702) | (4,377) | 1,324 | (9,595) | (7,287) | 2,308 |
| Total Expenditure | (39,147) | (37,812) | 1,334 | (60,273) | (58,279) | 1,994 |
| EBITDA | (17,164) | (16,110) | 1,054 | (26,458) | (24,142) | 2,316 |

| | ESM | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 71,265 | 70,988 | (276) | 106,087 | 105,793 | (294) |
| Total Pay | (41,325) | (40,391) | 934 | (62,896) | (61,509) | 1,387 |
| Non Pay | (16,149) | (16,226) | (77) | (24,009) | (24,037) | (28) |
| Total Expenditure | (57,473) | (56,616) | 857 | (86,905) | (85,546) | 1,359 |
| EBITDA | 13,791 | 14,372 | 581 | 19,182 | 20,247 | 1,065 |

| | ITAPS | | | | | |
|--------------------------|-----------------|-----------------|------------|--------------------|-------------------------|------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 14,034 | 14,041 | 8 | 21,036 | 21,044 | 8 |
| Total Pay | (26,294) | (26,290) | 4 | (40,164) | (40,160) | 4 |
| Non Pay | (7,608) | (7,361) | 247 | (11,403) | (11,156) | 247 |
| Total Expenditure | (33,902) | (33,652) | 251 | (51,567) | (51,316) | 251 |
| EBITDA | (19,869) | (19,610) | 258 | (30,530) | (30,272) | 258 |

| | MSS | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 39,233 | 39,249 | 16 | 58,615 | 58,646 | 31 |
| Total Pay | (19,649) | (19,318) | 331 | (30,000) | (29,318) | 682 |
| Non Pay | (8,059) | (6,733) | 1,326 | (15,247) | (11,328) | 3,920 |
| Total Expenditure | (27,709) | (26,051) | 1,658 | (45,247) | (40,646) | 4,602 |
| EBITDA | 11,524 | 13,198 | 1,673 | 13,368 | 18,001 | 4,632 |

Appendix 7: financial performance by CMG and directorate (2/2)

| | RRCV | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 71,330 | 71,406 | 75 | 107,060 | 107,186 | 126 |
| Total Pay | (29,697) | (29,342) | 355 | (45,404) | (44,226) | 1,178 |
| Non Pay | (22,156) | (20,742) | 1,414 | (33,740) | (31,289) | 2,451 |
| Total Expenditure | (51,852) | (50,083) | 1,769 | (79,144) | (75,515) | 3,629 |
| EBITDA | 19,478 | 21,322 | 1,844 | 27,916 | 31,671 | 3,755 |

| | W&C | | | | | |
|--------------------------|-----------------|-----------------|--------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 61,305 | 61,133 | (172) | 91,989 | 91,703 | (287) |
| Total Pay | (32,376) | (32,100) | 275 | (48,758) | (48,210) | 549 |
| Non Pay | (13,495) | (13,136) | 358 | (20,136) | (19,859) | 277 |
| Total Expenditure | (45,871) | (45,237) | 634 | (68,894) | (68,068) | 826 |
| EBITDA | 15,435 | 15,896 | 461 | 23,095 | 23,634 | 539 |

| | Estates and facilities | | | | | |
|--------------------------|------------------------|-----------------|-------------|--------------------|-------------------------|--------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 5,246 | 5,199 | (47) | 7,990 | 7,382 | (608) |
| Total Pay | (13,659) | (13,792) | (133) | (20,679) | (20,812) | (133) |
| Non Pay | (12,107) | (11,798) | 309 | (18,446) | (18,369) | 77 |
| Total Expenditure | (25,766) | (25,590) | 176 | (39,125) | (39,181) | (56) |
| EBITDA | (20,520) | (20,391) | 129 | (31,135) | (31,799) | (664) |

| | Corporate | | | | | |
|--------------------------|-----------------|-----------------|------------|--------------------|-------------------------|------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 4,774 | 4,974 | 200 | 7,096 | 7,507 | 411 |
| Total Pay | (13,712) | (13,655) | 57 | (20,564) | (20,512) | 52 |
| Non Pay | (17,195) | (16,413) | 782 | (26,920) | (26,522) | 398 |
| Total Expenditure | (30,907) | (30,067) | 840 | (47,484) | (47,034) | 450 |
| EBITDA | (26,133) | (25,093) | 1,040 | (40,388) | (39,527) | 861 |

| | R&I | | | | | |
|--------------------------|-----------------|-----------------|------------|--------------------|-------------------------|------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 12,420 | 12,488 | 68 | 18,311 | 19,069 | 759 |
| Total Pay | (5,181) | (5,161) | 19 | (7,791) | (7,743) | 49 |
| Non Pay | (6,657) | (6,261) | 396 | (9,891) | (9,432) | 458 |
| Total Expenditure | (11,838) | (11,423) | 415 | (17,682) | (17,175) | 507 |
| EBITDA | 582 | 1,065 | 483 | 628 | 1,894 | 1,266 |

| | Alliance | | | | | |
|--------------------------|----------------|----------------|-------------|--------------------|-------------------------|-------------|
| | YTD | | | Full year forecast | | |
| | Forecast | Actual | Variance | Forecast (M9) | Potential Outturn (M10) | Variance |
| | £000 | £000 | £000 | £000 | £000 | £000 |
| Total Income | 7,248 | 7,238 | (11) | 10,925 | 10,894 | (31) |
| Total Pay | (4,127) | (3,961) | 166 | (6,285) | (5,895) | 390 |
| Non Pay | (2,871) | (2,794) | 77 | (4,536) | (4,390) | 145 |
| Total Expenditure | (6,998) | (6,756) | 243 | (10,820) | (10,285) | 535 |
| EBITDA | 250 | 482 | 232 | 105 | 609 | 504 |

Appendix 8: statement of financial position

| £000 | Balance at 31 March 2020 | Current month | | | Forecast outturn | | |
|-------------------------------------------|-----------------------------|------------------|------------------|----------------|------------------|-----------------|----------------|
| | | 31-Dec-20 | 31-Jan-21 | Movement | 31-Mar-20 | Forecast | Movement |
| Non current assets | | | | | | | |
| Intangible assets | 6,570 | 4,973 | 4,441 | (532) | 6,570 | 4,425 | (2,145) |
| Property, plant and equipment | 529,798 | 539,724 | 540,279 | 555 | 529,798 | 559,945 | 30,147 |
| Other non-current assets | 2,533 | 1,759 | 1,663 | (96) | 2,533 | 2,134 | (399) |
| Total non-current assets | 538,901 | 546,456 | 546,383 | (73) | 538,901 | 566,504 | 27,603 |
| Current assets | | | | | | | |
| Inventories | 21,941 | 22,110 | 24,178 | 2,068 | 21,941 | 21,364 | (577) |
| Trade and other receivables | 52,156 | 47,634 | 53,461 | 5,827 | 52,156 | 46,794 | (5,362) |
| Cash and cash equivalents | 16,016 | 128,681 | 132,141 | 3,460 | 16,016 | 16,016 | 0 |
| Total current assets | 90,113 | 198,425 | 209,780 | 11,355 | 90,113 | 84,174 | (5,939) |
| Current liabilities | | | | | | | |
| Trade and other payables | (59,637) | (75,541) | (80,906) | (5,365) | (59,637) | (65,232) | (5,595) |
| Borrowings / leases | (339,814) | (1,093) | (1,093) | 0 | (339,814) | (1,093) | 338,721 |
| Accruals | (23,996) | (16,187) | (12,311) | 3,876 | (23,998) | (13,000) | 10,996 |
| Deferred income | (7,571) | (90,364) | (89,046) | 1,318 | (7,571) | (12,253) | (4,682) |
| Provisions < 1 year | (6,709) | (11,405) | (12,367) | (962) | (6,709) | (3,354) | 3,355 |
| Total current liabilities | (437,727) | (194,590) | (195,723) | (1,133) | (437,729) | (94,932) | 342,795 |
| Net current assets / (liabilities) | (347,615) | 3,835 | 14,057 | 10,222 | (347,616) | (10,758) | 336,857 |
| Non-current liabilities | | | | | | | |
| Borrowings / leases | (20,675) | (4,570) | (4,152) | 418 | (20,675) | (3,313) | 17,362 |
| Provisions for liabilities & charges | (7,041) | (8,755) | (8,755) | 0 | (7,041) | (8,755) | (1,714) |
| Total non-current liabilities | (27,716) | (13,325) | (12,907) | 418 | (27,716) | (12,068) | 15,648 |
| Total assets employed | 163,570 | 536,966 | 547,533 | 10,567 | 163,569 | 543,678 | 380,108 |
| Public dividend capital | 369,325 | 722,800 | 722,871 | 71 | 369,325 | 743,733 | 374,408 |
| Revaluation reserve | 168,342 | 168,342 | 168,342 | 0 | 168,342 | 168,342 | (0) |
| Income and expenditure reserve | (374,098) | (354,176) | (343,680) | 10,496 | (374,098) | (368,397) | 5,701 |
| Total taxpayers equity | 163,570 | 536,966 | 547,533 | 10,567 | 163,569 | 543,678 | 380,108 |

Current assets have increased by £11.4m in month driven by an increase in inventories of £2.1m and a £5.8m increase in receivables for both NHS and non NHS organisations.

Trade payables increased by £5.4m in month explained by the timing of supplier payments runs (payables pending approved for payment at month end but not processed in cash terms). This increase was offset by a reduction in expenditure accruals of £3.9m, as these costs transferred into the trade payable stage.

Year to date cash was significantly higher than plan due to the continued advancing of SLA payments by commissioners.

The Income and expenditure reserve increased in month by £10.5m in line with the improved I&E position reported in January.

Appendix 9: cashflow forecast

| Monthly cash flow £000 | Annual | Actual YTD | | | | | | | | | | Forecast | |
|---------------------------------------------|--------------------|------------------|------------------|-----------------|------------------|------------------|------------------|-----------------|------------------|------------------|-----------------|------------------|------------------|
| | | Apr | May | June | July | Aug | Sept | Oct | Nov | Dec | Jan | Feb | Mar |
| Receipts | | | | | | | | | | | | | |
| SLA block payments | 930,267 | 155,510 | 77,843 | 77,767 | 77,755 | 77,755 | 77,755 | 77,304 | 77,374 | 73,257 | 80,512 | 77,435 | 0 |
| COVID-19 top up | 143,380 | 20,555 | 13,592 | 12,539 | 10,263 | 10,263 | 10,263 | 0 | 17,202 | 13,732 | 13,732 | 10,999 | 10,240 |
| SLA performance (for prior years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Health education payments | 41,324 | 11,004 | 0 | 0 | 3,389 | 0 | 2,830 | 6,365 | 0 | 12,807 | 0 | 2,097 | 2,830 |
| Other NHS income | 58,646 | 10,836 | 6,080 | 7,801 | 2,697 | 3,512 | 3,383 | 3,518 | 5,947 | 3,986 | 2,898 | 4,218 | 3,770 |
| PDC - capital | 370,713 | 0 | 0 | 0 | 0 | 349,586 | 1,095 | 0 | 0 | 2,000 | 0 | 7,890 | 10,142 |
| TMP | 38,777 | 3,470 | 3,131 | 2,486 | 3,185 | 3,284 | 2,726 | 3,299 | 3,906 | 3,660 | 3,140 | 3,148 | 3,343 |
| Other non-NHS income | 46,882 | 3,827 | 4,958 | 3,169 | 5,575 | 6,156 | 2,654 | 4,793 | 2,428 | 5,187 | 2,828 | 2,654 | 2,654 |
| Total receipts | 1,629,988 | 205,202 | 105,605 | 103,761 | 102,863 | 450,555 | 100,706 | 95,280 | 106,857 | 114,629 | 103,110 | 108,441 | 32,979 |
| Salaries and wages | (690,860) | (55,409) | (57,033) | (57,778) | (57,742) | (57,466) | (57,549) | (57,885) | (57,059) | (58,668) | (58,271) | (58,271) | (57,728) |
| Creditor payments | (534,437) | (40,514) | (48,915) | (37,921) | (46,666) | (39,999) | (40,827) | (36,007) | (42,992) | (43,505) | (38,399) | (59,421) | (59,271) |
| NHS creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PDC dividend | (13,219) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1,949) | 0 | 0 | 0 | (11,270) |
| Repayment of loans | (349,586) | 0 | 0 | 0 | 0 | (349,586) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TMP | (40,070) | (4,265) | (2,445) | (2,322) | (3,353) | (2,876) | (2,539) | (3,692) | (3,736) | (4,284) | (2,861) | (4,284) | (3,413) |
| Total payments | (1,588,102) | (100,188) | (108,393) | (98,021) | (107,761) | (449,928) | (100,916) | (97,584) | (105,736) | (106,457) | (99,531) | (121,976) | (131,683) |
| Monthly cash movement | 41,886 | 105,014 | (2,788) | 5,740 | (4,898) | 627 | (210) | (2,304) | 1,121 | 8,172 | 3,579 | (13,535) | (98,703) |
| Cash in transit and cash in hand adjustment | (1,815) | 235 | 138 | (328) | (124) | 95 | 60 | (71) | 0 | 0 | 2,066 | (2,000) | (1,886) |
| Balance brought forward | 16,016 | 16,016 | 121,265 | 118,614 | 124,027 | 119,005 | 119,727 | 119,577 | 117,202 | 118,324 | 126,496 | 132,141 | 116,606 |
| Balance carried forward | 16,016 | 121,265 | 118,614 | 124,027 | 119,005 | 119,727 | 119,577 | 117,202 | 118,324 | 126,496 | 132,141 | 116,606 | 16,016 |
| Month End Cash Balance | 16,016 | 121,265 | 118,614 | 124,027 | 119,005 | 119,727 | 119,577 | 117,202 | 118,324 | 126,496 | 132,141 | 116,606 | 16,016 |

Included within SLA block payments is an advance payment of the 2020/21 block income. NHSE&I have confirmed that this will be reclaimed in Month 12, reducing our year end cash balance to £16m. The year end cash position is forecast to return to normalised levels (£16m), having now received confirmation that this payment regime will end in March (i.e. no patient care SLA income will be received in March). Capital payments will also accelerate in February and March inline with forecast, as well as settlement of the bi-annual PDC dividend charge.

Appendix 10: working capital (1/2)

| | Mar-20 | Q1 YTD | Q2 YTD | Q3 YTD | Month 10 YTD |
|----------------------------------------|--------|--------|--------|--------|--------------|
| Debtor and creditor days | | | | | |
| Debtor days | 18 | 9 | 12 | 20 | 17 |
| Creditor days | 75 | 87 | 88 | 91 | 97 |
| BPPC (cumulative) | | | | | |
| Value % | 67% | 92% | 92% | 93% | 93% |
| Volume % | 47% | 92% | 91% | 89% | 90% |
| BPPC (SMEs) paid within 30 days | | | | | |
| Value % | 13% | 69% | 64% | 63% | 59% |
| Volume % | 7% | 65% | 61% | 62% | 61% |
| BPPC (SMEs) paid within 5 days | | | | | |
| Value % | 13% | 24% | 20% | 18% | 19% |
| Volume % | 7% | 28% | 26% | 24% | 24% |

Aged NHS / non-NHS debt

Significant aged debt is currently being targeted for collection and an exercise undertaken during the last quarter to identify debts for potential write off.

BPPC

Performance has been broadly maintained across the year. The reduction in performance by volume from 92% in Q1 to 90% in Q3 is currently being investigated and appropriate actions will be taken to improve the performance up to the 95% target.

We have maintained our performance on SME payables from the prior month and are continuing to implement improvements to processes for these suppliers to improve performance against the 5 day payment target.

Aged NHS Payables and Receivables

NHS aged payables and receivables will be reviewed and appropriate escalation taken to reduce the over 90 day debt.

Appendix 10: working capital (2/2)

| | Total | 0 to 30 days | 31 to 60 days | 61 to 90 days | Over 90 days | Percentage over 90 days |
|---------------------------|---------------|---------------|---------------|---------------|--------------|-------------------------|
| January 2020 | £000 | £000 | £000 | £000 | £000 | % |
| Non-NHS receivables | 7,365 | 2,957 | 541 | 308 | 3,559 | 48% |
| NHS receivables | 5,128 | 3,813 | 381 | 82 | 852 | 17% |
| Total receivables | 12,493 | 6,770 | 922 | 390 | 4,411 | 35% |
| Bad debt provision | | | | | | |
| Non-NHS payables | 22,228 | 14,266 | 4,807 | 1,192 | 1,963 | 9% |
| NHS payables | 7,385 | 1,579 | 738 | 261 | 4,807 | 65% |
| Total payables | 29,613 | 15,845 | 5,545 | 1,453 | 6,770 | 23% |
| December 2020 | | | | | | |
| Non-NHS receivables | 6,610 | 1,469 | 596 | 792 | 3,753 | 57% |
| NHS receivables | 5,802 | 3,546 | 1,094 | 97 | 1,065 | 18% |
| Total receivables | 12,412 | 5,015 | 1,690 | 889 | 4,818 | 39% |
| Bad debt provision | | | | | | |
| Non-NHS payables | 17,206 | 12,906 | 2,102 | 707 | 1,491 | 9% |
| NHS payables | 8,610 | 1,657 | 1,131 | 603 | 5,219 | 61% |
| Total payables | 25,816 | 14,563 | 3,233 | 1,310 | 6,710 | 26% |

Appendix 11: capital programme

| Capital scheme | In month £000 | | | YTD £000 | | | Full year £000 |
|---------------------------------------------|---------------|--------------|----------------|---------------|---------------|----------------|-------------------|
| | Plan | Actual | Variance | Plan | Actual | Variance | M10 Forecast |
| Reconfiguration Scheme | 1,177 | 412 | (765) | 1,826 | 2,160 | 334 | 3,561 |
| ICU | | 178 | 178 | 8,496 | 7,024 | (1,472) | 7,682 |
| EMCHC | 1,104 | 1,651 | 547 | 4,793 | 6,851 | 2,058 | 10,618 |
| EMCHC equipment and enhancements | 0 | 0 | 0 | 0 | 974 | 974 | 1,475 |
| EMCHC Infrastructure | 167 | 122 | (45) | 1,065 | 0 | (1,065) | 711 |
| Gynae scheme - ward 29 | 0 | 0 | 0 | 720 | 0 | (720) | 532 |
| MEE 3T MRI Scanner | 1,760 | 305 | (1,455) | 0 | 1,417 | 1,417 | 3,177 |
| Medical Equipment | 621 | 203 | (418) | 1,097 | 1,269 | 172 | 3,645 |
| MES Replacement | 200 | 0 | (200) | 828 | 237 | (591) | 705 |
| MES Enabling Costs of MES | 60 | 17 | (43) | 343 | 0 | (343) | 500 |
| Additional medical equipment b/fwd | 0 | 0 | 0 | 0 | 0 | 0 | 1,322 |
| IM&T Infrastructure programme | 464 | 627 | 163 | 329 | 1,292 | 963 | 1,773 |
| IM&T eHospital | 131 | 183 | 52 | 1,410 | 959 | (451) | 1,274 |
| IM&T General | 0 | 0 | 0 | 0 | 0 | 0 | 596 |
| Digital Aspirant programme | 0 | 0 | 0 | 0 | 0 | 0 | 501 |
| HSLI | 0 | 0 | 0 | 0 | 0 | 0 | 1,673 |
| Critical Infrastructure Risk (CIR) | 0 | 365 | 365 | 1,361 | 0 | (1,361) | 4,263 |
| Slippage / Backlog / Other | 0 | 0 | 0 | 2,747 | 3,658 | 911 | 3,853 |
| Linear Accelerator + CT | 0 | 0 | 0 | 1,215 | 0 | (1,215) | 0 |
| Maternity Theatre Refurbishment | 0 | 0 | 0 | 750 | 0 | (750) | 0 |
| E&F Breakdown fund - defined schemes | 400 | 0 | (400) | 1,667 | 0 | (1,667) | 0 |
| Hope Expansion Project | 25 | 469 | 444 | 328 | 689 | 362 | 720 |
| ED Scheme | 400 | 284 | (116) | 444 | 381 | (63) | 2,419 |
| Car parking scheme ANPR | 0 | 0 | 0 | 0 | 0 | 0 | 1,377 |
| Covid-19 spend | 25 | 12 | (13) | 6,441 | 5,165 | (1,276) | 6,084 |
| Critical care wards - equipment | 0 | 0 | 0 | 0 | 0 | 0 | 1,270 |
| Endoscopy scheme | 350 | (252) | (602) | 926 | 1,464 | 538 | 3,418 |
| eQuip | 0 | 0 | 0 | 1,784 | 1,509 | (275) | 2,200 |
| Other - donated | 50 | 133 | 83 | 153 | 620 | 467 | 770 |
| Other | 0 | 378 | 378 | 578 | 549 | (29) | 4,982 |
| PMO office | 0 | 0 | 0 | 0 | 0 | 0 | 450 |
| Imaging Academy | 0 | 0 | 0 | 0 | 0 | 0 | 389 |
| Other schemes under £250k each (25 schemes) | 337 | 210 | (127) | 2,712 | 641 | (2,071) | 1,750 |
| Total | 7,271 | 5,297 | (1,974) | 42,012 | 36,859 | (5,153) | 73,690 |

Year to date underspend of £5.2m expected to be mitigated by the year end.

Impact of Covid-19 delaying schemes

The impact of Covid-19 on capital schemes has been assessed and built into the forecast outturn.

Funding opportunities and issues

Confirmation has been received that the Trust will receive approved Covid-19 capital funding of £4m. The remainder of the total Covid-19 related spend of £6.1m will be funded through a combination of internal funding and loan funding.

| Funding source | | £000 |
|----------------|-----------------------------------|---------------|
| A | Internally generated depreciation | 32,453 |
| B | Capital loans | 5,103 |
| C | COVID-19 | 3,912 |
| D | Finance lease | 7,068 |
| E | Other | 25,154 |
| Total | | 73,690 |